FibroBiologics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Details
| Name | FibroBiologics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 15 |
| Founded | 2021 |
| Ipo Date | 2024-01-31 |
| Ceo | Peter O’Heeron |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 30.00 |
| Isin | US31573L2043 |
| Cusip | 31573L204 |
| Cik | 1958777 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Peter O'Heeron | Founder, Chairperson and Chief Executive Officer |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
| Jason D. Davis CPA | Chief Financial Officer |
Contact
| Address | 455 East Medical Center Boulevard, Suite 300, Houston, Texas 77598, United States |
| Phone | 281 671 5150 |
| Website | https://fibrobiologics.com |